Trials / Completed
CompletedNCT04447924
The Effect of a Probiotic Strain on Ibuprofen-induced GI Damage
The Effect of Daily Intake of Bifidobacterium Breve Bif195 on Small-intestinal Damage Induced by Ibuprofen - a Randomized, Double-blind, Placebo-controlled Trial in Healthy Volunteers.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 177 (actual)
- Sponsor
- Chr Hansen · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
To investigate if a daily dose of minimum 15 billion CFU of Bif195 reduces the risk of small-intestinal tissue damage in an Ibuprofen challenge model as assessed by video capsule endoscopy in a healthy US population.
Detailed description
This trial is a single-site, randomized, double-blind, placebo-controlled, two-armed, parallel-group trial in healthy volunteers aged 18 - 40 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 or placebo when co-administered to daily intake of 800mg of Ibuprofen. The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and Ibuprofen is co-administered. Subjects will participate in the trial for a total duration of 8 weeks including the run-in phase. Besides the screening visit, the trial will consist of 5 visits. After having given their written informed consent, subjects will complete the screening procedures to evaluate their eligibility for participation in the trial and complete a run-in period of two weeks duration to washout possible pre-trial probiotics and/or use of medication. After baseline assessments at Visit 2, subjects will start daily intake of 800mg of Ibuprofen and also be randomly assigned to 6-weeks daily intake of Bif195 or placebo product in a ratio of 1:1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Bif195 | Daily intake of Bif195 dietary supplement |
| OTHER | Placebo | Daily intake of Placebo |
Timeline
- Start date
- 2020-06-22
- Primary completion
- 2021-06-10
- Completion
- 2021-06-10
- First posted
- 2020-06-25
- Last updated
- 2021-08-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04447924. Inclusion in this directory is not an endorsement.